Early research (Phase 1)Study completedNCT04702737What this trial is testingAMG 757 in Participants With Neuroendocrine Prostate CancerWho this might be right forNeuroendocrine Prostate Cancer Amgen 41
Not applicableStudy completedNCT00253708What this trial is testingMassage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic CancerWho this might be right forCancer Beth Israel Deaconess Medical Center 39
Testing effectiveness (Phase 2)Study completedNCT03365791What this trial is testingPDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesWho this might be right forSmall Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more Novartis Pharmaceuticals 76
Testing effectiveness (Phase 2)Study completedNCT02643303What this trial is testingTremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersWho this might be right forHead and Neck Squamous Cell CarcinomaBreast CancerSarcoma+8 more Ludwig Institute for Cancer Research 58
Early research (Phase 1)Looking for participantsNCT04485013What this trial is testingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersWho this might be right forCancer Tizona Therapeutics, Inc 240
Post-approval studies (Phase 4)Study completedNCT01794793What this trial is testingStudy to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesWho this might be right forCushing's DiseaseAcromegalyNeuroendocrine Tumors+6 more RECORDATI GROUP 337
Post-approval studies (Phase 4)Study completedNCT04074460What this trial is testingVolatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility StudyWho this might be right forCancer, BreastCancer ColorectalCancer Prostate+3 more Peter MacCallum Cancer Centre, Australia 169
Testing effectiveness (Phase 2)WithdrawnNCT05582031What this trial is testingRegorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable CancersWho this might be right forAnal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more Translational Research in Oncology
Testing effectiveness (Phase 2)Ended earlyNCT04926181What this trial is testingApalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerWho this might be right forSmall Cell Neuroendocrine CarcinomaProstate CancerSmall Cell Carcinoma Rahul Aggarwal 2
Not applicableStudy completedNCT01777802What this trial is testingImmune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or BrachytherapyWho this might be right forProstate CancerBreast CancerLung Cancer+1 more Mayo Clinic 98
Early research (Phase 1)Study completedNCT04148937What this trial is testingThe CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerWho this might be right forAdvanced Cancer Eli Lilly and Company 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT03360721What this trial is testingApalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaProstate Adenocarcinoma Without Neuroendocrine DifferentiationStage IV Prostate Cancer AJCC v8+2 more M.D. Anderson Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT00940225What this trial is testingStudy of Cabozantinib (XL184) in Adults With Advanced MalignanciesWho this might be right forSolid TumorsCancer Exelixis 730
Early research (Phase 1)Study completedNCT00375245What this trial is testingRapamycin With Grapefruit Juice for Advanced MalignanciesWho this might be right forTumorsNeoplasm Metastasis University of Chicago 41
Early research (Phase 1)Study completedNCT00004065What this trial is testingChemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerWho this might be right forBladder CancerBreast CancerColorectal Cancer+9 more Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06943521What this trial is testingMT-4561 in Patients With Various Advanced Solid TumorsWho this might be right forHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more Tanabe Pharma America, Inc. 27
Testing effectiveness (Phase 2)Study completedNCT00818480What this trial is testingAn Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155Who this might be right forProstate CancerMelanomaNon-Hodgkin's Lymphoma Astellas Pharma Inc 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727What this trial is testingA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Who this might be right forSmall-Cell Lung CancerNeuroendocrine Carcinoma Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232
Not applicableStudy completedNCT02966509What this trial is testingEngagement of Patients With Advanced CancerWho this might be right forEnd of LifeAdvanced CancerLung Neoplasm+11 more Stanford University 213
Early research (Phase 1)Not Yet RecruitingNCT07177937What this trial is testingDXC014 in Patients With Advanced Solid Tumors.Who this might be right forSmall Cell Lung CancerMelanomaProstate Cancer+1 more Hangzhou DAC Biotechnology Co., Ltd. 150